Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4-α4 interface

Neuropharmacology

Volumn 92, Issue , 2015, Pages 135-145

  Ahring, Philip K ^a,b   Olsen, Jeppe A ^a,c,d   Nielsen, Elsebet ^c   Peters, Dan ^e   Pedersen, Martin H F ^f   Rohde, Line A ^c,d   Kastrup, Jette S ^d   Shahsavar, Azadeh ^d   Indurthi, Dinesh C ^a   Chebib, Mary ^a   Gajhede, Michael ^d   Balle, Thomas ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Saniona AB ^*  (Denmark)

^c NEUROSEARCH A S   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e DanPET AB   (Sweden)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Cys loop receptor; Electrophysiology; Ion channel; Nicotinic acetylcholine receptor (nAChR); Pharmacology; Radioligand binding

Indexed keywords

1 (5 ETHOXYPYRIDIN 3 YL) 1,4 DIAZEPANE; 1 (5 ETHOXYPYRIDIN 3 YL) 1,4 DIAZEPANE H 3; 1 (5 VINYLOXYPYRIDIN 3YL) 1,4 DIAZEPANE; 1 (5 VINYLOXYPYRIDIN 3YL) 1,4 DIAZEPANE H 3; 1 (6 BROMOPYRIDIN 3 YL) 1,4 DIAZEPANE; 1 (6 BROMOPYRIDIN 3 YL) 1,4 DIAZEPANE H 3; 1 (PYRIDIN 3 YL) 1,4 DIAZEPANE; 1 (PYRIDIN 3 YL) 1,4 DIAZEPANE H 3; EPIBATIDINE; EPIBATIDINE H 3; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1-(5-ETHOXYPYRIDIN-3-YL)-1,4-DIAZEPANE; ACETYLCHOLINE; AZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NICOTINE; NICOTINIC RECEPTOR; PROTEIN BINDING; PROTEIN SUBUNIT; PYRIDINE DERIVATIVE; TRITIUM;

AFFINITY LABELING; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOASSAY; RECEPTOR BINDING ASSAY; RECEPTOR UPREGULATION; STOICHIOMETRY; WILD TYPE; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; DOSE RESPONSE; DRUG EFFECTS; ELECTROSTIMULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; MEMBRANE POTENTIAL; METABOLISM; OOCYTE; PROTEIN SUBUNIT; XENOPUS LAEVIS;

ACETYLCHOLINE; ANIMALS; AZEPINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; HEK293 CELLS; HUMANS; MEMBRANE POTENTIALS; MODELS, MOLECULAR; NICOTINE; NICOTINIC AGONISTS; OOCYTES; PROTEIN BINDING; PROTEIN SUBUNITS; PYRIDINES; RECEPTORS, NICOTINIC; TRANSFECTION; TRITIUM; XENOPUS LAEVIS;

EID: 84922381735     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.12.035     Document Type: Article

References (36)

1. N.L. Absalom, G. Quek, T.M. Lewis, T. Qudah, I. von Arenstorff, and J.I. Ambrus Covalent trapping of methyllycaconitine at the α4-α4 interface of the α4β2 nicotinic acetylcholine receptor: antagonist binding site and mode of receptor inhibition revealed J. Biol. Chem. 288 2013 26521 26532
2. E.E. Bain, W. Robieson, Y. Pritchett, T. Garimella, W. Abi-Saab, and G. Apostol A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD Neuropsychopharmacology 38 2013 405 413
3. D. D'Hoedt, and D. Bertrand Nicotinic acetylcholine receptors: an overview on drug discovery Expert Opin. Ther. Targets 13 2009 395 411
4. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors J. Pharmacol. Exp. Ther. 282 1997 445 451
5. J.M. Frost, W.H. Bunnelle, K.R. Tietje, D.J. Anderson, L.E. Rueter, and P. Curzon Synthesis and structure-activity relationships of 3,8-diazabicyclo[4.2.0]octane ligands, potent nicotinic acetylcholine receptor agonists J. Med. Chem. 49 2006 7843 7853
6. 2 nicotinic ACh receptors Br. J. Pharmacol. 168 2013 2000 2010
7. K. Harpsøe, P.K. Ahring, J.K. Christensen, M.L. Jensen, D. Peters, and T. Balle Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors J. Neurosci. 31 2011 10759 10766
8. K. Harpsøe, H. Hald, D.B. Timmermann, M.L. Jensen, T. Dyhring, and E.∅. Nielsen Molecular determinants of subtype-selective efficacies of cytisine and the novel compound NS3861 at heteromeric nicotinic acetylcholine receptors J. Biol. Chem. 288 2013 2559 2570
9. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain Mol. Pharmacol. 48 1995 280 287
10. J. Ji, M.R. Schrimpf, K.B. Sippy, W.H. Bunnelle, T. Li, and D.J. Anderson Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel α4β2 nicotinic acetylcholine receptor selective agonists J. Med. Chem. 50 2007 5493 5508
11. S. Leonard, S. Mexal, and R. Freedman Smoking, genetics and schizophrenia: evidence for self medication J. Dual Diagn. 3 2007 43 59
12. M.J. Marks, K.W. Smith, and A.C. Collins Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain J. Pharmacol. Exp. Ther. 285 1998 377 386
13. 3H]epibatidine Mol. Pharmacol. 70 2006 947 959
14. + efflux with high and low sensitivity to stimulation by acetylcholine Neuropharmacology 53 2007 390 405
15. M.J. Marks, D.S. Laverty, P. Whiteaker, O. Salminen, S.R. Grady, and J.M. McIntosh John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes J. Mol. Neurosci. 40 2010 96 104
16. C.B. Marotta, I. Rreza, H.A. Lester, and D.A. Dougherty Selective ligand behaviors provide new insights into agonist activation of nicotinic acetylcholine receptors ACS Chem. Biol. 9 2014 1153 1159
17. 2α4 nicotinic receptor influences agonist sensitivity J. Biol. Chem. 286 2011 31043 31054
18. S. Mazzaferro, F. Gasparri, K. New, C. Alcaino, M. Faundez, and P. Iturriaga Vasquez Non-equivalent ligand selectivity of agonist sites in (α4β2)2α4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy J. Biol. Chem. 289 2014 21795 21806
19. N.R. Mirza, J.S. Larsen, C. Mathiasen, T.A. Jacobsen, G. Munro, and H.K. Erichsen NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy J. Pharmacol. Exp. Ther. 327 2008 954 968
20. M. Moroni, R. Zwart, E. Sher, B.K. Cassels, and I. Bermudez alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine Mol. Pharmacol. 70 2006 755 768
21. 2+ potentiation J. Neurosci. 28 2008 6884 6894
22. M.E. Nelson, A. Kuryatov, C.H. Choi, Y. Zhou, and J. Lindstrom Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors Mol. Pharmacol. 63 2003 332 341
23. J.A. Olsen, J.S. Kastrup, D. Peters, M. Gajhede, T. Balle, and P.K. Ahring Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors J. Biol. Chem. 288 2013 35997 36006
24. J.A. Olsen, P.K. Ahring, J.S. Kastrup, M. Gajhede, and T. Balle Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptors J. Biol. Chem. 289 2014 24911
25. J.A. Olsen, T. Balle, M. Gajhede, P.K. Ahring, and J.S. Kastrup Molecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptors PLoS One 9 2014 e91232
26. A.M. Person, and G.B. Wells Characterizing low affinity epibatidine binding to α4β2 nicotinic acetylcholine receptors with ligand depletion and nonspecific binding BMC Biophys. 4 2011 19
27. A.H. Rezvani, and E.D. Levin Cognitive effects of nicotine Biol. Psychiatry 49 2001 258 267
28. L.A. Rohde, P.K. Ahring, M.L. Jensen, E.∅. Nielsen, D. Peters, and C. Helgstrand Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine α4β2 receptors: unique role of halogen bonding revealed J. Biol. Chem. 287 2012 4248 4259
29. M.C. Rowbotham, W.R. Duan, J. Thomas, W. Nothaft, and M.M. Backonja A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain Pain 146 2009 245 252
30. N. Shafaee, M. Houng, A. Truong, N. Viseshakul, A. Figl, and S. Sandhu Pharmacological similarities between native brain and heterologously expressed α4β2 nicotinic receptors Br. J. Pharmacol. 128 1999 1291 1299
31. A. Taly, P.J. Corringer, D. Guedin, P. Lestage, and J.P. Changeux Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discov. 8 2009 733 750
32. D.B. Timmermann, J.H. Grønlien, K.L. Kohlhaas, E.O. Nielsen, E. Dam, and T.D. Jørgensen An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo J. Pharmacol. Exp. Ther. 323 2007 294 307
33. D.B. Timmermann, K. Sandager-Nielsen, T. Dyhring, M. Smith, A.M. Jacobsen, and E.∅. Nielsen Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors Br. J. Pharmacol. 167 2012 164 182
34. P. Tosco, P.K. Ahring, T. Dyhring, D. Peters, K. Harpsøe, and T. Liljefors Complementary three-dimensional quantitative structure-activity relationship modeling of binding affinity and functional potency: a study on α4β2 nicotinic ligands J. Med. Chem. 52 2009 2311 2316
35. A. Truong, X. Xing, J.R. Forsayeth, L.P. Dwoskin, P.A. Crooks, and B.N. Cohen Pharmacological differences between immunoisolated native brain and heterologously expressed rat α4β2 nicotinic receptors Brain Res. Mol. Brain Res. 96 2001 68 76
36. R. Zwart, A.L. Carbone, M. Moroni, I. Bermudez, A.J. Mogg, and E.A. Folly Sazetidine-A is a potent and selective agonist at native and recombinant α4β2 nicotinic acetylcholine receptors Mol. Pharmacol. 73 2008 1838 1843